Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia.
Footshock stress induces both endocannabinoid mobilization and antinociception. The present studies investigated behavioral plasticity in cannabinoid antinociceptive mechanisms following repeated activation using the tail-flick test. A secondary objective was to ascertain whether blockade of stress antinociception by the CB(1) antagonist rimonabant could be attributed to changes in locomotor activity. The cannabinoid agonist WIN55,212-2 induced hypoactivity in the open field relative to vehicle-treated controls. By contrast, rimonabant, administered at a dose that virtually eliminated endocannabinoid-mediated stress antinociception, failed to alter locomotor behavior (i.e. time resting, ambulatory counts, distance traveled) in rats subjected to the same stressor. Rats exposed acutely to footshock were hypersensitive to the antinociceptive effects of WIN55,212-2 and Delta(9)-tetrahydrocannabinol (Delta(9)-THC). The converse was also true; acute Delta(9)-THC and WIN55,212-2 administration potentiated stress antinociception, suggesting a bidirectional sensitization between endocannabinoid-mediated stress antinociception and exogenous cannabinoid antinociception. Stress antinociception was also attenuated following chronic relative to acute treatment with WIN55,212-2 or Delta(9)-THC. Repeated exposure to footshock (3 min/day for 15 days), however, failed to attenuate antinociception induced by either footshock stress or WIN55,212-2. Our results demonstrate that endocannabinoid-mediated stress antinociception cannot be attributed to motor suppression. Our results further identify a functional plasticity of the cannabinoid system in response to repeated activation. The existence of cross-sensitization between endocannabinoid-mediated stress antinociception and exogenous cannabinoid antinociception suggests that these phenomena are mediated by a common mechanism. The observation of stress-induced hypersensitivity to effects of exogenous cannabinoids may have clinical implications for understanding marijuana abuse liability in humans.
Suplita
Richard L
RL
Neuroscience and Behavior Program, Department of Psychology, University of Georgia, Athens, GA 30602-3013, USA.
Eisenstein
Sarah A
SA
Neely
Mark H
MH
Moise
Anna M
AM
Hohmann
Andrea G
AG
D000700:Analgesics / Q000627:therapeutic use*; D000704:Analysis of Variance; D000818:Animals; D001522:Behavior, Animal; D048588:Benzoxazines / Q000627:therapeutic use*; D063385:Cannabinoid Receptor Modulators / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013759:Dronabinol / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004361:Drug Tolerance / Q000502:physiology; D004597:Electroshock / Q000009:adverse effects; D063388:Endocannabinoids; D008297:Male; D009025:Morpholines / Q000627:therapeutic use*; D009043:Motor Activity / Q000187:drug effects; D009281:Naphthalenes / Q000627:therapeutic use*; D010147:Pain Measurement; D010880:Piperidines / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011930:Reaction Time / Q000187:drug effects; D000077285:Rimonabant; D013312:Stress, Physiological / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D013997:Time Factors
D000700:Analgesics; D048588:Benzoxazines; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D009025:Morpholines; D009281:Naphthalenes; D010880:Piperidines; D011720:Pyrazoles; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; D013759:Dronabinol; D000077285:Rimonabant
Neuron. 2006 Aug 17;51(4):455-66
16908411
Science. 2006 Jun 30;312(5782):1967-70
16809545
Neuropharmacology. 2007 Feb;52(2):415-22
17011598
Curr Opin Lipidol. 2007 Apr;18(2):129-40
17353660
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 13;31(3):633-41
17258369
Brain Res. 1986 Mar 12;368(1):101-6
3955348
Eur J Neurosci. 2001 Sep;14(5):884-6
11576193
Psychopharmacology (Berl). 2001 Nov;158(3):259-66
11713615
Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):269-85
12052042
Nature. 2002 Aug 1;418(6897):530-4
12152079
Pharmacol Biochem Behav. 2002 Nov;73(4):911-9
12213538
J Adolesc. 2002 Dec;25(6):645-54
12490182
Neuron. 2003 May 8;38(3):461-72
12741992
Physiol Rev. 2003 Jul;83(3):1017-66
12843414
Curr Opin Chem Biol. 2003 Aug;7(4):469-75
12941421
Pharmacol Biochem Behav. 2003 Jul;75(4):809-21
12957223
Nat Rev Neurosci. 2003 Nov;4(11):873-84
14595399
Science. 1980 May 9;208(4444):623-5
7367889
J Neurosci. 1981 Apr;1(4):358-63
7264724
Pain. 1983 Jun;16(2):109-10
6877845
J Pers Soc Psychol. 1986 Sep;51(3):564-77
3489832
Pharmacol Biochem Behav. 1991 Nov;40(3):471-8
1666911
Brain Res. 1993 Jul 9;616(1-2):293-302
8395305
J Neurosci. 1996 Oct 15;16(20):6601-11
8815936
Nature. 1998 Sep 24;395(6700):381-3
9759727
Endocrinology. 2004 Dec;145(12):5431-8
15331569
Neuropsychopharmacology. 2005 Mar;30(3):497-507
15280883
Neuropsychopharmacology. 2005 Mar;30(3):508-15
15525997
Neuropsychopharmacology. 2005 Mar;30(3):516-24
15637635
Eur J Neurosci. 2005 Feb;21(4):1057-69
15787710
J Pharmacol Exp Ther. 2005 Jul;314(1):329-37
15831444
Pharmacol Biochem Behav. 2005 Jun;81(2):331-42
15927244
Pharmacol Biochem Behav. 2005 Jun;81(2):387-95
15935455
Nature. 2005 Jun 23;435(7045):1108-12
15973410
Curr Opin Investig Drugs. 2005 Jul;6(7):672-9
16044662
Neuropharmacology. 2005 Dec;49(8):1201-9
16129456
Neuropharmacology. 2006 Mar;50(3):372-9
16316669
Neurosci Lett. 2006 Apr 24;397(3):180-4
16378681
Handb Exp Pharmacol. 2005;(168):367-83
16596781
Handb Exp Pharmacol. 2005;(168):509-54
16596786
Handb Exp Pharmacol. 2005;(168):691-717
16596793
Trends Neurosci. 2006 Apr;29(4):225-32
16483675
J Neurosci. 2006 Jun 21;26(25):6677-86
16793875
Curr Med Chem. 2006;13(22):2669-80
17017918